Australia markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
946.87-1.18 (-0.12%)
At close: 04:00PM EST
948.60 +1.73 (+0.18%)
After hours: 08:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 103.99B
Enterprise value 95.85B
Trailing P/E 27.25
Forward P/E 21.14
PEG ratio (5-yr expected) 1.93
Price/sales (ttm)8.21
Price/book (mrq)4.00
Enterprise value/revenue 7.31
Enterprise value/EBITDA 20.42

Trading information

Stock price history

Beta (5Y monthly) 0.11
52-week change 326.73%
S&P500 52-week change 325.42%
52-week high 3973.99
52-week low 3684.81
50-day moving average 3908.94
200-day moving average 3815.28

Share statistics

Avg vol (3-month) 3570.59k
Avg vol (10-day) 3492.52k
Shares outstanding 5107.94M
Implied shares outstanding 6109.76M
Float 8102.8M
% held by insiders 12.53%
% held by institutions 189.34%
Shares short (31 Jan 2024) 41.25M
Short ratio (31 Jan 2024) 42.21
Short % of float (31 Jan 2024) 41.35%
Short % of shares outstanding (31 Jan 2024) 41.14%
Shares short (prior month 29 Dec 2023) 41.06M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 30.14%
Operating margin (ttm)29.20%

Management effectiveness

Return on assets (ttm)8.49%
Return on equity (ttm)16.26%

Income statement

Revenue (ttm)13.12B
Revenue per share (ttm)122.93
Quarterly revenue growth (yoy)0.60%
Gross profit (ttm)N/A
EBITDA 4.65B
Net income avi to common (ttm)3.95B
Diluted EPS (ttm)34.79
Quarterly earnings growth (yoy)-3.10%

Balance sheet

Total cash (mrq)10.84B
Total cash per share (mrq)100.92
Total debt (mrq)2.7B
Total debt/equity (mrq)10.41%
Current ratio (mrq)5.69
Book value per share (mrq)242.47

Cash flow statement

Operating cash flow (ttm)4.59B
Levered free cash flow (ttm)2.77B